DescriptionCurator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364036 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BACITRACIN Approved UseUses first aid to help prevent infection in: •minor cuts •scrapes •burns Launch Date1948 |
|||
Curative | CORTISPORIN Approved UseFor the treatment of corticosteroid-responsice dermatoses with secondary infection. Launch Date1957 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. Launch Date1968 |
PubMed
Title | Date | PubMed |
---|---|---|
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo. | 1948 Mar |
|
Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene. | 1950 Feb |
|
Detection by HPLC-ICP of metallothionein in serum of an epileptic child with valproate-associated hepatotoxicity. | 1992 Dec |
|
Differential dephosphorylation of the insulin receptor and its 160-kDa substrate (pp160) in rat adipocytes. | 1992 Jul 15 |
|
Intestinal damage induced by zinc deficiency is associated with enhanced CuZn superoxide dismutase activity in rats: effect of dexamethasone or thyroxine treatment. | 1999 May |
|
Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. | 1999 Sep 10 |
|
The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. | 2000 Feb 15 |
|
Regulation of metallothionein gene expression by oxidative stress and metal ions. | 2000 Jan 1 |
|
Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. | 2000 May |
|
Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein. | 2000 Nov 28 |
|
cDNA array analysis identifies thymic LCK as upregulated in moderate murine zinc deficiency before T-lymphocyte population changes. | 2001 Dec |
|
Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT. | 2001 Feb 28 |
|
Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. | 2001 Mar |
|
p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis. | 2001 May 15 |
|
Loss of vesicular zinc and appearance of perikaryal zinc after seizures induced by pilocarpine. | 2001 May 25 |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Influence of dietary zinc deficiency during development on hepatic CYP2C11, CYP2C12, CYP3A2, CYP3A9, and CYP3A18 expression in postpubertal male rats. | 2001 Nov 1 |
|
Modulation of intestinal gene expression by dietary zinc status: effectiveness of cDNA arrays for expression profiling of a single nutrient deficiency. | 2001 Nov 20 |
|
Metallothionein is required for zinc-induced expression of the macrophage colony stimulating factor gene. | 2002 |
|
Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle. | 2002 Dec 13 |
|
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone. | 2002 Jan 15 |
|
Partitioning of accumulated trace metals in the talitrid amphipod crustacean Orchestia gammarellus: a cautionary tale on the use of metallothionein-like proteins as biomarkers. | 2002 Jun |
|
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. | 2002 Nov |
|
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation. | 2002 Oct |
|
Effect of chromium on apolipoprotein A-I expression in HepG2 cells. | 2003 Apr |
|
The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice. | 2003 Aug 29 |
|
Effects of zinc occupancy on human O6-alkylguanine-DNA alkyltransferase. | 2003 Feb 4 |
|
Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice. | 2003 Jan |
|
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites. | 2003 Jun |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. | 2003 Oct |
|
Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate. | 2003 Oct 3 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration:
Topical
Substance Class |
Mixture
Created
by
admin
on
Edited
Sat Dec 16 17:50:15 GMT 2023
by
admin
on
Sat Dec 16 17:50:15 GMT 2023
|
Record UNII |
58H6RWO52I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
1284
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
WHO-VATC |
QR02AB04
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
WHO-ATC |
J01XX10
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
CFR |
21 CFR 333.120
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
CFR |
21 CFR 524.155
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
WHO-ATC |
R02AB04
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
CFR |
21 CFR 556.70
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
EPA PESTICIDE CODE |
6302
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
CFR |
21 CFR 333.110
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
CFR |
21 CFR 524.154
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
CFR |
21 CFR 520.154
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
WHO-ATC |
D06AX05
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
WHO-VATC |
QJ01XX10
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
WHO-VATC |
QD06AX05
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
||
|
WHO-VATC |
QA07AA93
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BACITRACIN
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
215-786-2
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
755905
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
SUB00652MIG
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
1291
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | RxNorm | ||
|
BACITRACIN
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. | ||
|
DB00626
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
C295
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
1167
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
m2197
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
N0000008479
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | Decreased Cell Wall Synthesis & Repair [PE] | ||
|
Bacitracin
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
D001414
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
1405-87-4
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200558
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
281
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY | |||
|
28669
Created by
admin on Sat Dec 16 17:50:16 GMT 2023 , Edited by admin on Sat Dec 16 17:50:16 GMT 2023
|
PRIMARY |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
MIC
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SUB_CONCEPT->SUBSTANCE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
http://apps.who.int/phint/pdf/b/Jb.6.1.40.pdf
|